Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review
V Vannappagari, L Ragone, C Henegar… - Antiviral …, 2019 - journals.sagepub.com
Background Pretreatment and acquired drug resistance mutations (DRMs) can limit
antiretroviral therapy effectiveness. Methods We review prevalence of DRMs with resistance …
antiretroviral therapy effectiveness. Methods We review prevalence of DRMs with resistance …
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT …
V Miller, M Stürmer, S Staszewski, B Gröschel… - Aids, 1998 - journals.lww.com
Objective: To investigate the prevalence and magnitude of M 184 V-mediated changes in
susceptibility to zalcitabine, didanosine, stavudine and abacavir (1592U89 succinate) in a …
susceptibility to zalcitabine, didanosine, stavudine and abacavir (1592U89 succinate) in a …
Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons
V Calvez, AG Marcelin, J Vingerhoets, A Hill… - Antiviral …, 2016 - journals.sagepub.com
Background Transmitted drug resistance to antiretrovirals in HIV-1-infected individuals is
rising in some regions and could compromise the effectiveness of first-line treatment. It is …
rising in some regions and could compromise the effectiveness of first-line treatment. It is …
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping …
R Montejano, L Dominguez-Dominguez… - Journal of …, 2021 - academic.oup.com
Background Previously selected lamivudine resistance-associated mutations (RAMs) may
remain archived within the proviral HIV-DNA. Objectives To evaluate the ability of proviral …
remain archived within the proviral HIV-DNA. Objectives To evaluate the ability of proviral …
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review …
RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri… - The Lancet infectious …, 2009 - thelancet.com
Antiretroviral-therapy rollout in resource-poor countries is often associated with limited, if
any, HIV-RNA monitoring. The effect of variable monitoring on the emergence of resistance …
any, HIV-RNA monitoring. The effect of variable monitoring on the emergence of resistance …
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine
S Gallien, I Charreau, ML Nere… - Journal of …, 2015 - academic.oup.com
Objectives Efavirenz and nevirapine failure is associated with a rapid selection of resistance-
associated mutations (RAMs), which may impact on etravirine or rilpivirine susceptibility …
associated mutations (RAMs), which may impact on etravirine or rilpivirine susceptibility …
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa
Nonnucleoside reverse transcriptase inhibitor–drug resistance mutations (DRM) are
increasingly reported in Africans failing their first antiretroviral regimen. The Phidisa II trial …
increasingly reported in Africans failing their first antiretroviral regimen. The Phidisa II trial …
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003–2010
MD Miller, M Haddad, C Su, C Gibbs… - Antiviral …, 2012 - journals.sagepub.com
Background The selection of antiretroviral (ARV) drugs for treatment of HIV-1 infection is
based on several factors including potency, toxicity, resistance and ease of administration …
based on several factors including potency, toxicity, resistance and ease of administration …
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
T Bunupuradah, J Ananworanich… - Antiviral …, 2011 - journals.sagepub.com
Background We studied prevalence of etravirine (ETR) and rilpivirine (RPV) resistance in
HIV-1 subtype CRF01_AE infection with first-line non-nucleoside reverse transcriptase …
HIV-1 subtype CRF01_AE infection with first-line non-nucleoside reverse transcriptase …
Transmitted drug resistance to rilpivirine among antiretroviral‐naïve patients living with HIV from northern Poland
M Parczewski, A Urbańska… - Journal of the …, 2014 - Wiley Online Library
Introduction Rilpivirine (RPV) is a second‐generation non‐nucleoside reverse transcriptase
inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral‐naïve …
inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral‐naïve …